Ekso Bionics’ (EKSO) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Ekso Bionics (NASDAQ:EKSO) in a report issued on Tuesday morning,Benzinga reports. HC Wainwright currently has a $9.00 price objective on the stock. HC Wainwright also issued estimates for Ekso Bionics’ Q1 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.25) EPS, FY2026 earnings at $0.00 EPS, FY2027 earnings at $0.12 EPS, FY2028 earnings at $0.27 EPS and FY2029 earnings at $0.46 EPS.

Separately, StockNews.com started coverage on Ekso Bionics in a report on Monday. They set a “hold” rating on the stock.

Ekso Bionics Trading Down 8.0 %

NASDAQ EKSO opened at $0.40 on Tuesday. The company has a market capitalization of $8.86 million, a price-to-earnings ratio of -0.62 and a beta of 1.46. The stock’s 50-day simple moving average is $0.61 and its two-hundred day simple moving average is $0.82. The company has a quick ratio of 2.14, a current ratio of 2.81 and a debt-to-equity ratio of 0.28. Ekso Bionics has a twelve month low of $0.37 and a twelve month high of $1.64.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.07). The company had revenue of $5.09 million during the quarter, compared to analysts’ expectations of $5.05 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. Research analysts forecast that Ekso Bionics will post -0.48 EPS for the current fiscal year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.